154 related articles for article (PubMed ID: 37296228)
1. Loss of SFXN1 mitigates lipotoxicity and predicts poor outcome in non-viral hepatocellular carcinoma.
Yagi K; Shimada S; Akiyama Y; Hatano M; Asano D; Ishikawa Y; Ueda H; Watanabe S; Akahoshi K; Ono H; Tanabe M; Tanaka S
Sci Rep; 2023 Jun; 13(1):9449. PubMed ID: 37296228
[TBL] [Abstract][Full Text] [Related]
2. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
3. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma.
Kubo S; Takemura S; Tanaka S; Shinkawa H; Nishioka T; Nozawa A; Kinoshita M; Hamano G; Ito T; Urata Y
World J Gastroenterol; 2015 Jul; 21(27):8249-55. PubMed ID: 26217076
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B viral load affects prognosis of hepatocellular carcinoma.
Yu SJ; Kim YJ
World J Gastroenterol; 2014 Sep; 20(34):12039-44. PubMed ID: 25232241
[TBL] [Abstract][Full Text] [Related]
5. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506
[TBL] [Abstract][Full Text] [Related]
6. Effects of Positive Hepatitis B Core Antibody and Metabolic Disorders in Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus.
Lee HL; Bae SH; Lee J; Sung PS; Lee SW; Jang JW; Lee J; Choi JY; Han NI; Yoon SK
Cancer Control; 2021; 28():10732748211039758. PubMed ID: 34569320
[TBL] [Abstract][Full Text] [Related]
7. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma.
Chong CC; Wong GL; Lai PB
World J Gastroenterol; 2014 May; 20(20):6006-12. PubMed ID: 24876723
[TBL] [Abstract][Full Text] [Related]
8. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma.
Lee SS; Jeong SH; Byoun YS; Chung SM; Seong MH; Sohn HR; Min BY; Jang ES; Kim JW; Park GJ; Lee YJ; Lee KH; Ahn S
BMC Cancer; 2013 Jul; 13():335. PubMed ID: 23829392
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
Liang YJ; Teng W; Chen CL; Sun CP; Teng RD; Huang YH; Liang KH; Chen YW; Lin CC; Su CW; Tao MH; Wu JC
Hepatology; 2021 Aug; 74(2):641-655. PubMed ID: 33675094
[TBL] [Abstract][Full Text] [Related]
11. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.
Kurhe Y; Caputo M; Cansby E; Xia Y; Kumari S; Anand SK; Howell BW; Marschall HU; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2022; 13(2):405-423. PubMed ID: 34624527
[TBL] [Abstract][Full Text] [Related]
12. SRXN1 stimulates hepatocellular carcinoma tumorigenesis and metastasis through modulating ROS/p65/BTG2 signalling.
Lv X; Yu H; Zhang Q; Huang Q; Hong X; Yu T; Lan H; Mei C; Zhang W; Luo H; Pang P; Shan H
J Cell Mol Med; 2020 Sep; 24(18):10714-10729. PubMed ID: 32746503
[TBL] [Abstract][Full Text] [Related]
13. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
Nagata H; Nakagawa M; Asahina Y; Sato A; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Nouchi T; Sakai H; Tomita M; Watanabe M;
J Hepatol; 2017 Nov; 67(5):933-939. PubMed ID: 28627363
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area.
Lee SB; Kim KM; An J; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS
Liver Int; 2016 Sep; 36(9):1351-61. PubMed ID: 26913702
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma xenograft supports HCV replication: a mouse model for evaluating antivirals.
Hazari S; Hefler HJ; Chandra PK; Poat B; Gunduz F; Ooms T; Wu T; Balart LA; Dash S
World J Gastroenterol; 2011 Jan; 17(3):300-12. PubMed ID: 21253388
[TBL] [Abstract][Full Text] [Related]
16. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
[TBL] [Abstract][Full Text] [Related]
18. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study.
Wang ZY; Tao QF; Wang ZH; Lin KY; Huang G; Yang Y; Zhou WP; Lau WY
Am J Surg; 2020 Apr; 219(4):717-725. PubMed ID: 31266631
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we.
Tsoulfas G
World J Gastroenterol; 2019 Aug; 25(29):3842-3848. PubMed ID: 31413522
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
